StreetSpread · Technology · Kalshi

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Jan 1, 2028?

Technology Closes January 1, 2028 Kalshi

Kalshi's current ask is 90¢ for YES on this contract (90% implied). Closes January 1, 2028 (~412 days).

Live price

Side	Cents	Implied	Volume
Kalshi (yes ask)	90¢	90%	$1K
Kalshi (yes bid)	81¢	81%	—

Trade on Kalshi →

Don't just watch the number

Today's top 5 gaps →The five most actionable spreads across every venue right now — free. Ask Ace about this market →3 free questions with the AI analyst — in the app. Track it live →Real-time spreads, price history, and alerts on your phone.

Get the app →Live on the App Store — every venue priced side by side, in your pocket.

StreetSpread aggregates real-time odds across Kalshi, Polymarket, DraftKings, FanDuel, BetMGM, Caesars, and Fanatics. Prices refresh about every two minutes. Back to live tracker · Get the app.

Follow us: X (@thestreetspread) · Instagram (@thestreetspread) · LinkedIn